---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-068306"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2026-05-29T20:30:49+00:00"
generated_at: "2026-05-29T20:34:01.701139+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Outlook Therapeutics sells 8.54M shares to GMS Ventures in registered direct offering

## Summary
- 8,539,709 shares of common stock sold to GMS Ventures and Investments under a securities purchase agreement dated May 28, 2026.
- Offering made via effective S-3 shelf registration statement (File No. 333-278340).
- No per-share price or gross proceeds disclosed in the filing.
- Shares issued under a registered direct offering; closing expected on or about May 29, 2026.

## SEC filing metadata
- accession: 0001104659-26-068306
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2026-05-29T20:30:49+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465926068306/0001104659-26-068306-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926068306/tm2615979d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-068306
- JSON: https://secwatch.observer/filing/0001104659-26-068306.json
- Plain text: https://secwatch.observer/filing/0001104659-26-068306.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.